Anika Therapeutics, Inc. ANIK
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -3.78M | -11.06M | -10.88M | -33.04M | -60.63M |
| Total Depreciation and Amortization | 5.63M | 5.40M | 5.58M | 5.70M | 6.48M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.22M | 21.88M | 17.31M | 37.53M | 65.40M |
| Change in Net Operating Assets | -15.10M | -9.74M | -823.00K | -2.06M | -4.97M |
| Cash from Operations | 5.98M | 6.47M | 11.19M | 8.13M | 6.28M |
| Capital Expenditure | -5.42M | -5.43M | -6.83M | -7.49M | -6.81M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | 4.50M | 8.99M | 8.99M | 8.99M |
| Other Investing Activities | 1.36M | -2.38M | -2.57M | -3.41M | -4.17M |
| Cash from Investing | -4.05M | -3.31M | -401.00K | -1.91M | -1.99M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 449.00K | 500.00K | 500.00K | 558.00K | 558.00K |
| Repurchase of Common Stock | -16.79M | -15.96M | -11.05M | -11.18M | -15.16M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -16.34M | -15.46M | -10.55M | -10.63M | -14.60M |
| Foreign Exchange rate Adjustments | -339.00K | -51.00K | 86.00K | 21.00K | 660.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.76M | -12.35M | 322.00K | -4.38M | -9.66M |